Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL15568303 | 0.96 | GSK3B (0.40) | GSK3BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21232810 | 0.87 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DALPL | |
| SCHEMBL10072627 | 0.84 | GSK3B (0.41) | GSK3BALPLPLAAALPGKCNJ1 | |
| SCHEMBL3426851 | 0.82 | KCNJ1 (0.54) | PDE4APDE4BPDE4CPDE4DALPL | |
| SCHEMBL652235 | 0.81 | PDE4A (0.54) | GSK3BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15069904 | 0.77 | ALPL (0.44) | GSK3BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15069906 | 0.77 | ALPL (0.36) | GSK3BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8297460 | 0.76 | CYP3A4 (0.56) | GAA | |
| SCHEMBL641907 | 0.75 | GSK3B (0.57) | GSK3BPTPN1KDM4E | |
| SCHEMBL8297464 | 0.75 | ALPL (0.39) | ALPLPLAAALPGKCNJ1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585455-B1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | UNIV CALIFORNIA (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2885306-B1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2885306-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014026881-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | GSK3B 172/4885PDE4A 279/4885PDE4B 200/4885 |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | IAPP, APP, BACE1 | GSK3B 511/4885PDE4A 791/4885PDE4B 627/4885 |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | APP, BACE1, BACE2 | GSK3B 172/4885PDE4A 279/4885PDE4B 200/4885 |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | MAPT, SNCA, PARK7 | GSK3B 170/4885PDE4A 3888/4885PDE4B 3621/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | GSK3B 294/4885PDE4A 491/4885PDE4B 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.